©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2017; 23(23): 4311-4316
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4311
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4311
Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation
Ji-Lai Bian, Mei-Mei Wang, En-Juan Tong, Jing Sun, Ming Li, Department of Medical Oncology, The Fifth People’s Hospital of Dalian, Dalian 116021, Liaoning Province, China
Zhi-Bo Miao, Yan-Lin Li, Bai-Hong Zhu, Origimed Inc, Shanghai 201114, China
Jia-Jia Xu, Institute of Precision Medicine, 3D Medicines Inc, Shanghai 201114, China
Author contributions: Bian JL and Wang MM followed the patient; Miao ZB, Li YL, Zhu BH and Xu JJ provided genetic analysis for the variants tested in the patient; Tong EJ, Sun J and Li M searched related articles; Bian JL and Li YL wrote the paper; all authors have read and approved the final manuscript.
Conflict-of-interest statement: There are no potential conflicts of interest relevant to this article.
Correspondence to: Dr. Ji-Lai Bian, Department of Medical Oncology, The Fifth People’s Hospital of Dalian, Dalian 116021, Liaoning Province, China. bianjilai123@126.com
Telephone: +86-411-842112244 Fax: +86-411-842112244
Received: February 26, 2017
Peer-review started: February 27, 2017
First decision: April 10, 2017
Revised: April 22, 2017
Accepted: May 19, 2017
Article in press: May 19, 2017
Published online: June 21, 2017
Processing time: 113 Days and 16.7 Hours
Peer-review started: February 27, 2017
First decision: April 10, 2017
Revised: April 22, 2017
Accepted: May 19, 2017
Article in press: May 19, 2017
Published online: June 21, 2017
Processing time: 113 Days and 16.7 Hours
Core Tip
Core tip: We report a stage IV intrahepatic cholangiocarcinoma (ICC) patient harboring a PIK3CA mutation who responded well to the mTOR inhibitor everolimus. Computed tomography and magnetic resonance imaging demonstrated shrinkage of the tumor and the maintenance of partial response for 6.5 mo after everolimus treatment as the best response. To the best of our knowledge, this is the first clinical case report in the literature of an ICC patient with PIK3CA mutation deriving benefit from everolimus treatment.